CA4 and neoplasm: Combretastatin A4 phosphate (CA4P), a prodrug of CA-4, and ombrabulin (AVE8062), a synthetic analog of CA4P (Fig. 1), have been shown to suppress tumor growth by reducing tumor blood flow in different cancers in vivo [12–15].